Nerlynx — Medical Mutual
Breast Cancer, Limited or Extensive Brain Metastases
Initial criteria
- Patient has recurrent brain metastases and stable systemic disease
- Nerlynx will be used in combination with capecitabine or paclitaxel
- Patient has HER2-positive breast cancer
Reauthorization criteria
- Extended approval is 1 year for approvable indications
Approval duration
1 year